Inflammatory bowel diseases (IBD) including colitis and Crohn’s disease, impact millions worldwide. Increasing cases and inadequate treatment options highlight the need for translatable models to advance preclinical research into IBD therapeutics.
Taconic Biosciences offers access to three major classes of IBD mouse models, sold with full use rights for drug discovery and development. As the in vivo microbiome leader, Taconic offers the most options for investigating the microbiome as it relates to IBD.